

nNOS-c-Terminus blocking peptide

Data Sheet

Catalog Number: P24287 Format: Lyophilize-25 ug

Description: AFIEESKKDTDEVFS Molecular weight: 1745 daltons

conjugated to KLH
Control Antigen for use in absorption

control.

Application Notes

The peptide control for nNOS (C-terminal) is intended for the immuno-adsorption of nNOS (C-terminal) antiserum, catalog number RA24287. Pre-adsorption of nNOS (C-terminal) antiserum, diluted according to the antibody specification sheet, with 5 ug/ml nNOS peptide immunogen following the instructions below provides complete blockage of nNOS (C-terminal) immunolabeling. The peptide is provided as 25ug of lyophilized human nNOS, sequence 1419-1433.

Storage/Handling:

- Do not reconstitute until ready to use since the product is most stable when lyophilized. The product does not
 need to be kept cooled during shipping. Prior to reconstitution, store at -15 to -25°C. The crystals in the vial may
 be difficult to see and the vial may appear empty.
- Reconstitute vial with 500 ul of Phosphate Buffered Saline/Triton X-100 (0.05M sodium phosphate, 0.15M sodium chloride, 0.3% Triton X-100, pH 7.4), put the stopper back, invert the vial, and vortex.
- After reconstitution, use immediately or refrigerate at 2º-8º C up to 2 days. For long-term storage, appropriately aliquot antibody to avoid repeated freeze/thaw cycles and freeze at -15 to -25°C.

Blocking Protocol:

- 1. Follow the instructions for reconstitution of the lyophilized peptide above.
- 2. Add 100 ul of the reconstituted peptide per milliliter of diluted antibody to achieve a final peptide concentration of 5
- 3. Vortex the diluted antibody/peptide solution and incubate at 2 to 8 °C for 18-24 hours before use.
- 4. Always run pre-adsorbed antibody in parallel with untreated antibody. Untreated antibody should stain appropriately, while pre-adsorbed antibody should provide complete blockage of immunolabeling.

FOR RESEARCH USE ONLY

NEUROMICS ANTIBODIES REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.

www.neuromics.com